[ad_1]
A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL.
Medscape Medical News
[ad_2]
Source link : https://www.medscape.com/viewarticle/venetoclax-obinutuzumab-boosts-mrd-clearance-cll-2026a1000mqf?src=rss
Author :
Publish date : 2026-07-06 08:59:00
Copyright for syndicated content belongs to the linked Source.